SCHEMBL5886274

SCHEMBL5886274

CNS(=O)(=O)c1ccc2c(ccc3nc4cccc(C(=O)O)c4nc32)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.45
NQO2 P16083 1/20 0.41
MTNR1A P48039 1/20 0.41
CSNK2A1 P68400 1/20 0.39
SCN9A Q15858 1/20 0.39
CYP2C9 P11712 1/20 0.38
ATIC P31939 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RAD52 P43351 1/20 0.38
UTRN P46939 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SIRT5 Q9NXA8 1/20 0.37
KDR P35968 1/20 0.37
NR1H2 P55055 1/20 0.36
BRAF P15056 1/20 0.36
TNNI3K Q59H18 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886246 0.84 ALDH1A1 (0.51) ALDH1A1CYP2C9ATICCYP2C19HSD17B10
SCHEMBL5886389 0.84 ALDH1A1 (0.51) ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL5886269 0.84 ALDH1A1 (0.48) ALDH1A1RAD52MEN1KMT2A
SCHEMBL5886412 0.81 ALDH1A1 (0.48) ALDH1A1CYP2C9CYP2C19HSD17B10RAD52
SCHEMBL5886374 0.81 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP2C9CYP2C19RAD52
SCHEMBL5886502 0.80 KDM4E (0.52) ALDH1A1L3MBTL1HSD17B10RAD52MEN1
SCHEMBL5886363 0.79 ALDH1A1 (0.56) ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL5886283 0.78 ALDH1A1 (0.55) ALDH1A1CYP2C9CYP2C19HSD17B10RAD52
SCHEMBL5886371 0.77 KDM4E (0.52) ALDH1A1NQO2MTNR1AHSD17B10MEN1
SCHEMBL5886494 0.76 ALDH1A1 (0.50) ALDH1A1CSNK2A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A ALDH1A1 3766/4885L3MBTL1 3563/4885NQO2 982/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B ALDH1A1 2334/4885L3MBTL1 3169/4885NQO2 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.